Whole-brain connectivity in a large study of Huntington's disease gene mutation carriers and healthy controls.

Espinoza FA, Turner JA, Vergara VM, Miller RL, Mennigen E, Liu J, Misiura MB, Ciarochi J, Johnson HJ, Long JD, Bockholt HJ, Magnota VA, Paulsen JS, Calhoun VD.

Brain Connect. 2018 Jan 1. doi: 10.1089/brain.2017.0538. [Epub ahead of print]

Abnormal Photic Entrainment to Phase-Delaying Stimuli in the R6/2 Mouse Model of Huntington's Disease, despite Retinal Responsiveness to Light.

Ouk K, Aungier J, Ware M, Morton AJ.

eNeuro. 2019 Dec 10;6(6). pii: ENEURO.0088-19.2019. doi: 10.1523/ENEURO.0088-19.2019. Print 2019 Nov/Dec.

The impact of different types of assistive devices on gait measures and safety in Huntington's disease.

Kloos AD, Kegelmeyer DA, White SE, Kostyk SK.

PLoS One. 2012;7(2):e30903. doi: 10.1371/journal.pone.0030903.

Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole.

Howard AK, Krishnamoorthy A, Leavitt BR, Raymond LA, Weissman CR.

J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):e211-2. doi: 10.1176/appi.neuropsych.14090232. No abstract available.

Longitudinal characterization of mGluR5 using (11)C-ABP688 PET imaging in the Q175 mouse model of Huntington's disease.

Bertoglio D, Kosten L, Verhaeghe J, Thomae D, Wyffels L, Stroobants S, Wityak J, Dominguez C, Mrzljak L, Staelens S.

J Nucl Med. 2018 May 24. pii: jnumed.118.210658. doi: 10.2967/jnumed.118.210658. [Epub ahead of print]

Erucic acid, a nutritional PPARδ-ligand may influence Huntington's disease pathogenesis.

Altinoz MA, Ozpinar A, Ozpinar A, Hacker E.

Metab Brain Dis. 2020 Jan;35(1):1-9. doi: 10.1007/s11011-019-00500-6. Epub 2019 Oct 17. Review.

Key role of nuclear medicine in seeking biomarkers of Huntington's disease.

Squitieri F, Ciarmiello A.

Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1124-7. doi: 10.1007/s00259-010-1439-8. No abstract available.

The Tiny Drosophila Melanogaster for the Biggest Answers in Huntington's Disease.

Rosas-Arellano A, Estrada-Mondragón A, Piña R, Mantellero CA, Castro MA.

Int J Mol Sci. 2018 Aug 14;19(8). pii: E2398. doi: 10.3390/ijms19082398. Review.

Huntington's disease: the value of transcranial meganetic stimulation.

Medina FJ, Túnez I.

Curr Med Chem. 2010;17(23):2482-91.

The role of immunity in Huntington's disease.

Soulet D, Cicchetti F.

Mol Psychiatry. 2011 Sep;16(9):889-902. doi: 10.1038/mp.2011.28. Review.

Female Sexual Dysfunction in Presymptomatic Mutation Carriers and Patients with Huntington's Disease.

Kolenc M, Kobal J, Podnar S.

J Huntingtons Dis. 2017 May 5. doi: 10.3233/JHD-160224. [Epub ahead of print]

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators.; REGISTRY investigators., Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.

Control of Huntington's Disease-Associated Phenotypes by the Striatum-Enriched Transcription Factor Foxp2.

Hachigian LJ, Carmona V, Fenster RJ, Kulicke R, Heilbut A, Sittler A, Pereira de Almeida L, Mesirov JP, Gao F, Kolaczyk ED, Heiman M.

Cell Rep. 2017 Dec 5;21(10):2688-2695. doi: 10.1016/j.celrep.2017.11.018.

Use of electroconvulsive therapy in a patient with chorea neuroacanthocytosis and prominent delusions.

Rutherford M.

J ECT. 2012 Jun;28(2):e5-6. doi: 10.1097/YCT.0b013e31823c071d.

Automated Assessment of Movement Impairment in Huntington's Disease.

Bennasar M, Hicks YA, Clinch SP, Jones P, Holt C, Rosser A, Busse M.

IEEE Trans Neural Syst Rehabil Eng. 2018 Oct;26(10):2062-2069. doi: 10.1109/TNSRE.2018.2868170.